Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1973 1
1976 3
1977 1
1978 1
1979 1
1981 1
1982 3
1983 1
1986 1
1987 2
1988 1
1989 1
1990 2
1991 2
1992 4
1993 3
1994 1
1995 6
1996 3
1997 2
1998 3
1999 3
2000 3
2001 3
2002 5
2003 1
2004 3
2005 6
2006 2
2007 1
2008 1
2009 1
2010 2
2014 2
2015 1
2017 2
2018 1
2019 3
2020 1
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Ornithine carbamoyltransferase deficiency.
Wraith JE. Wraith JE. Arch Dis Child. 2001 Jan;84(1):84-88. doi: 10.1136/adc.84.1.84. Arch Dis Child. 2001. PMID: 11124797 Free PMC article. Review. No abstract available.
Liver transplantation in rare late-onset ornithine transcarbamylase deficiency with central nervous system injury: A case report and review of the literature.
Jin X, Zeng X, Zhao D, Jiang N. Jin X, et al. Brain Behav. 2022 Oct;12(10):e2765. doi: 10.1002/brb3.2765. Epub 2022 Sep 20. Brain Behav. 2022. PMID: 36128655 Free PMC article. Review.
BACKGROUND: Ornithine transcarbamylase deficiency (OTCD) is a genetic metabolic disease. ...His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finall …
BACKGROUND: Ornithine transcarbamylase deficiency (OTCD) is a genetic metabolic disease. ...His first symptoms were non …
[Preliminary study of glyceryl phenylbutyrate therapy for Ornithine transcarbamylase deficiency and a literature review].
Zhou D, Shang X, Qiao Y, Cheng Y, Yu Z, Huang X. Zhou D, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023 Sep 10;40(9):1107-1112. doi: 10.3760/cma.j.cn511374-20220624-00423. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023. PMID: 37643956 Review. Chinese.
OBJECTIVE: To evaluate the efficacy and safety of glyceryl phenylbutyrate (GPB) therapy for patients with Ornithine transcarbamylase deficiency (OTCD). METHODS: Two children with OTCD were selected as the study subjects, and their clinical manifestations, blood ammo …
OBJECTIVE: To evaluate the efficacy and safety of glyceryl phenylbutyrate (GPB) therapy for patients with Ornithine transcarbamylase …
[Consensus on diagnosis and treatment of ornithine trans-carbamylase deficiency].
Division of Genetics and Metabolism, Child Diseases and Health Care Branch, Chinese Association for Maternal and Child Health. Division of Genetics and Metabolism, Child Diseases and Health Care Branch, Chinese Association for Maternal and Child Health. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Oct 25;49(5):539-547. doi: 10.3785/j.issn.1008-9292.2020.04.11. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 33210478 Free PMC article. Review. Chinese.
Ornithine transcarbamylase deficiency(OTCD)is a most common ornithine cycle (urea cycle) disorder. ...Patients with neonatal onset usually have complete absence of OTC enzyme activity, which is mainly associated with male semi-zygotic mutations; and the di
Ornithine transcarbamylase deficiency(OTCD)is a most common ornithine cycle (urea cycle) disorder. ...Patients with neo
Messenger RNA therapy for rare genetic metabolic diseases.
Berraondo P, Martini PGV, Avila MA, Fontanellas A. Berraondo P, et al. Gut. 2019 Jul;68(7):1323-1330. doi: 10.1136/gutjnl-2019-318269. Epub 2019 Feb 22. Gut. 2019. PMID: 30796097 Review.
Here we summarise this new class of drugs and discuss the preclinical evidence supporting the potential of liver-mediated mRNA therapy for three rare genetic conditions: methylmalonic acidaemia, acute intermittent porphyria and ornithine transcarbamylase deficiency. …
Here we summarise this new class of drugs and discuss the preclinical evidence supporting the potential of liver-mediated mRNA therapy for t …
Ornithine transcarbamylase deficiency: pathogenesis of the cerebral disorder and new prospects for therapy.
Michalak A, Butterworth RF. Michalak A, et al. Metab Brain Dis. 1997 Sep;12(3):171-82. Metab Brain Dis. 1997. PMID: 9346466 Review.
Ornithine Transcarbamylase (OTC) is a key urea cycle enzyme. Congenital OTC deficiencies in humans result in hyperammonemia and a spectrum of neurological symptoms including hypotonia, seizures and mental retardation. ...Possible pathophysiologic mechanisms responsible for
Ornithine Transcarbamylase (OTC) is a key urea cycle enzyme. Congenital OTC deficiencies in humans result in hyperammonemia and a spe
Valproate-induced hyperammonemic encephalopathy.
Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Segura-Bruna N, et al. Acta Neurol Scand. 2006 Jul;114(1):1-7. doi: 10.1111/j.1600-0404.2006.00655.x. Acta Neurol Scand. 2006. PMID: 16774619 Review.
There are several studies that suggest that treatment with supplements of carnitine can lead to an early favorable clinical response due to the probable carnitine deficiency induced by a valproate (VPA) treatment. Development of the progressive confusional syndrome, associ …
There are several studies that suggest that treatment with supplements of carnitine can lead to an early favorable clinical response due to …
Citrulline in health and disease. Review on human studies.
Papadia C, Osowska S, Cynober L, Forbes A. Papadia C, et al. Clin Nutr. 2018 Dec;37(6 Pt A):1823-1828. doi: 10.1016/j.clnu.2017.10.009. Epub 2017 Oct 16. Clin Nutr. 2018. PMID: 29107336 Review.
The amino acid L-citrulline (CIT) is safely used from the neonatal period onwards in those with urea cycle defects and carbamyl phosphate synthetase or ornithine transcarbamylase deficiencies, but several lines of enquiry indicate that it might have a much wider therapeuti …
The amino acid L-citrulline (CIT) is safely used from the neonatal period onwards in those with urea cycle defects and carbamyl phosphate sy …
Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.
Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Caldovic L, et al. J Genet Genomics. 2015 May 20;42(5):181-94. doi: 10.1016/j.jgg.2015.04.003. Epub 2015 May 19. J Genet Genomics. 2015. PMID: 26059767 Free PMC article. Review.
Ornithine transcarbamylase (OTC) deficiency is an X-linked trait that accounts for nearly half of all inherited disorders of the urea cycle. ...In the 2006 update, 341 mutations were reported. This current update contains 417 disease-causing mutations, and al
Ornithine transcarbamylase (OTC) deficiency is an X-linked trait that accounts for nearly half of all inherited disorders of t
Marginal parental donors for pediatric living donor liver transplantation.
Kasahara M, Sakamoto S, Fukuda A, Uchida H, Yi NJ, Schlegel A, Muiesan P, Qiang X, Gao W, Zhu ZJ, Rodriguez-Davalos M, Rela M. Kasahara M, et al. Curr Opin Organ Transplant. 2022 Aug 1;27(4):346-350. doi: 10.1097/MOT.0000000000000990. Curr Opin Organ Transplant. 2022. PMID: 36354261 Review.
Indications for LT have evolved not only for cholestatic liver disease, but also metabolic liver diseases. Living donor selection, particularly for pediatric inherited disease, is essential to prevent morbidity, both in the donor and recipient. RECENT FINDINGS: Base …
Indications for LT have evolved not only for cholestatic liver disease, but also metabolic liver diseases. Living donor selection, pa …
88 results